12 results on '"Tianyue Zhou"'
Search Results
2. Nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa
3. Mini-COMET study: Effects of 97 weeks of avalglucosidase alfa dosing on ptosis in participants with infantile-onset Pompe disease who were previously treated with alglucosidase alfa
4. The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
5. Avalglucosidase alfa immunogenicity in alglucosidase alfa-experienced participants with Pompe disease: Pooled analysis of clinical trial data
6. Analysis of pooled data from clinical trials in treatment-naïve patients with late-onset Pompe disease (LOPD) to inform on the efficacy of avalglucosidase alfa
7. Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline
8. Home-infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials (COMET, NEO-EXT, and Mini-COMET)
9. Baby-COMET methodology: A clinical study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of avalglucosidase alfa in treatment-naïve participants with IOPD
10. Baby-COMET methodology: a study of the efficacy and safety of avalglucosidase alfa in treatment-naïve IOPD ≤6 months of age
11. Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients
12. Characterization of anti-agalsidase beta antibody formation from clinical trials and the Fabry Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.